Progress with biological agents in metastatic colorectal cancer leads to many challenges

Journal of Clinical Oncology

Volumn 24, Issue 21, 2006, Pages 3325-3327

  Van Cutsem, Eric ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EDITORIAL; HUMAN; METASTASIS; MONOTHERAPY; PRIORITY JOURNAL; COLORECTAL TUMOR; METABOLISM; NOTE; PHASE 2 CLINICAL TRIAL; SURVIVAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33746797393     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.2067     Document Type: Editorial

References (28)

1. Van Cutsem E, Hoff PM, Harper P, et al: Oral capecitabine vs intravenous 5-flourouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomised phase III trials. Br J Cancer 90:1190-1197, 2004
2. De Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
3. Saltz L, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914, 2000
4. Douillard J, Cunningham D, Roth A, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
5. Rothenberg M, Oza A, Bigelow R, et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 21:2059-2069, 2003
6. Cunningham D, Pyrhonen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418, 1998
7. Rougier P, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412, 1998
8. Hurwitz H, Fehrenbacher L, Novotny, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
9. Giantonio BJ, Catalano P, Meropol N, et al: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 23: 1s, 2005 (abstr 2)
10. Kabbinavar F, Schulz J, McLeod, et al: Addition of bevacizumab to bolus flourouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 23:3697-3705, 2005
11. Hurwitz H, Fehrenbacher L, Hainsworth J, et al: Bevacizumab in combinatie with flourouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502-3508, 2005
12. Kabbinavar F, Hambleton J, Mass R, et al: Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706-3712, 2005
13. Hochster H, Hart R, Ramanathan J, et al: Results of the tree-2 cohort: Safety, tolerability, and efficacy of bevacizumab added to three oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer. American Society of Clinical Oncology Gastrointestinal Cancer Symposium, 2006 (abstr 244)
14. Saltz L, Meropol N, Loehrer P, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208, 2004
15. Lenz HJ, Mayer RJ, Gold PJ, et al: Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. J Clin Oncol 22:247s, 2004 (abstr 3510)
16. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
17. Malik I, Hecht J, Patnaik A, et al: Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer. J Clin Oncol 23:251s, 2005 (abstr 3520)
18. Vallbohmer D, Zhang W, Gordon M, et al: Molecular determinants of cetuximab efficacy. J Clin Oncol 23:3536-3544, 2005
19. Moroni M, Veronese S, Benvenuti S, et al: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 6:279-286, 2005
20. Jubb A, Hurwitz H, Bai W, et al: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 24:217-227, 2006
21. Ince W, Jubb A, Holden SN, et al: Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 97:981-989, 2005
22. Chen H, Mooney M, Boron M, et al: Multicenter phase II trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced colorectal cancer that progressed after standard chemotherapy: NCI treatment referral center trial TRC-0301. J Clin Oncol 24:3354-3360, 2006
23. Saltz L, Lenz H, Hochster H, et al: Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J Clin Oncol 23:248s, 2005 (abstr 3508)
24. Folprecht G, Lutz M, Schoffski P, et al: Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17:450-456, 2006
25. Diaz-Rubio E, Tabernero J, Van Cutsem E, et al: Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study. J Clin Oncol 23:254s, 2005 (abstr 3535)
26. Fong Y, Cohen A, Fortner J, et al: Liver resection for colorectal metastases. J Clin Oncol 15:938-946, 1997
27. Adam R, Avisar E, Ariche A, et al: Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8:347-353, 2001
28. Folprecht G, Grothey A, Alberts S, et al: Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol 16:1311-1319, 2005